Navigation Links
Merck & Co., Inc. Named Keynote Sponsor For Diversity Alliance For Science's Inaugural Conference

Global Pharmaceutical Company Supports Organization's National Networking

And Expo Event

MORRISTOWN, N.J., March 28 /PRNewswire/ -- Diversity Alliance for Science, Inc. (DA4S) ( has announced that Merck & Co., Inc. will serve as the keynote sponsor for its inaugural networking conference and expo scheduled for May 19-20 at the Westin Governors in Morristown, N.J. The two-day event will focus on developing and integrating more minority, women, veteran and disabled-owned businesses into the life sciences space. The national event is expected to draw top-level pharmaceutical executives, high-ranking government officials and CEOs of diverse scientific and clinical enterprises.

Merck & Co, Inc. is one of the largest pharmaceutical companies in the world. Established in 1891 and headquartered in Whitehouse Station, N.J., the company discovers, develops, manufactures and markets a broad range of products aimed at improving human and animal health. Merck has 59,800-plus employees worldwide and products sold in more than 140 countries. The company boasts a Manufacturing Division, which employs more than 12,000 people at locations in 25 countries, as well as The Merck Research Laboratories, which employs approximately 9,500 people at sites in the U.S., Canada, Europe and Asia. Through The Merck Foundation, founded in 1957, the company has distributed more than $480 million to educational and nonprofit organizations worldwide.

"Merck's success has been built from the diversity of its employees and from a diverse customer base," said Sally Macaluso, senior director of global procurement for Merck & Co., Inc. "One of Merck's key corporate objectives is to grow supplier diversity spend to support the diverse communities in which we do business. As such, Merck is a proud sponsor of Diversity Alliance For Science's 'Diversity Creates Scientific Innovation Conference and Expo.'"

About Diversity Alliance for Science, Inc. (DA4S):

Diversity Alliance for Science, Inc. (DA4S) is a nonprofit organization aimed to provide pharmaceutical/bio-tech companies, academic medical centers and governmental agencies the ability to identify, develop, mentor and partner with woman, minority, veteran and disabled-owned enterprises (both large and small) in the life sciences industry. For more information, please visit

Patty Briguglio

MMI Associates, Inc.

(919) 233-6600

PR Firms Raleigh, NC

SOURCE Diversity Alliance for Science, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
2. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
3. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
4. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
5. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
6. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
7. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
8. Miaxis Biometrics Named as Red Herring 100 Asia Award Winner for 2007
9. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
10. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
11. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):